ProShare Advisors
SLS icon

ProShare Advisors’s SELLAS Life Sciences SLS Stock Holding History

ProShare Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$365K Sell
24,711
-204
-0.8% -$1.41K ﹤0.01% 1296
2026
Q1 		$105K Buy
24,915
+2,277
+10% +$10.2K ﹤0.01% 1697
2025
Q4 		$85.3K Buy
22,638
+5,417
+31% +$10.5K ﹤0.01% 1896
2025
Q3 		$27.7K Sell
17,221
-2,350
-12% -$4.19K ﹤0.01% 1975
2025
Q2 		$42.9K Buy
+19,571
New +$30K ﹤0.01% 2009

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

ProShare Advisors's SLS Position: Q2 2026 in Review

ProShare Advisors reduced its SELLAS Life Sciences (SLS) stake by 0.82% in Q2 2026, selling an estimated $1.41K and leaving 24,711 shares worth $365K. The position accounts for ﹤0.01% of the portfolio, ranked #1296.

ProShare Advisors first reported a position in SLS in Q2 2025 and has held it in 5 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • ProShare Advisors held 24,711 shares of SELLAS Life Sciences worth $365K as of Q2 2026.
  • ProShare Advisors sold 204 SELLAS Life Sciences shares in Q2 2026, an estimated $1.41K.
  • SELLAS Life Sciences made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1296 holding.
  • ProShare Advisors first reported a position in SELLAS Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.